224 related articles for article (PubMed ID: 16651443)
1. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
[TBL] [Abstract][Full Text] [Related]
3. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
4. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
Berquin IM; Pang B; Dziubinski ML; Scott LM; Chen YQ; Nolan GP; Ethier SP
Oncogene; 2005 Apr; 24(19):3177-86. PubMed ID: 15735691
[TBL] [Abstract][Full Text] [Related]
5. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
Lee C; Dhillon J; Wang MY; Gao Y; Hu K; Park E; Astanehe A; Hung MC; Eirew P; Eaves CJ; Dunn SE
Cancer Res; 2008 Nov; 68(21):8661-6. PubMed ID: 18974106
[TBL] [Abstract][Full Text] [Related]
6. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE
Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491
[TBL] [Abstract][Full Text] [Related]
7. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
8. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
9. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
[TBL] [Abstract][Full Text] [Related]
10. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
11. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
12. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
[TBL] [Abstract][Full Text] [Related]
13. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.
Merrick DT; Kittelson J; Winterhalder R; Kotantoulas G; Ingeberg S; Keith RL; Kennedy TC; Miller YE; Franklin WA; Hirsch FR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2281-8. PubMed ID: 16609045
[TBL] [Abstract][Full Text] [Related]
14. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
19. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
[TBL] [Abstract][Full Text] [Related]
20. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.
Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O
Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
